Biolidics partners Japan's Sysmex Corp for cancer-related R&D

Biolidics partners Japan's Sysmex Corp for cancer-related R&D

By: 
Michelle Zhu
20/02/19, 06:19 pm

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.

See: Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

The endeavor will use Biolidic’s ClearCell FX1 System and Sysmex’s molecular imaging flow cytometer MI-FCM in Japan and Singapore, respectively.

Under the non-binding term sheet signed by both parties today, Biolidics and Sysmex intend to laboratory assay developments, applications and market developments for the potential commercialisation of these laboratory assays.

In a Wednesday filing, Biolidics says its ClearCell FX1 System has the potential to serve as a platform technology for the diagnosis, prognosis, treatment selection and treatment monitoring of various types of cancers, through the development of a wide range of clinical or laboratory assays.

With Sysmex as a strategic partner, the group believes this will enhance the commercial scalability of its technology and allowing the ClearCell FX1 System to be used in a greater number of hospitals and laboratories globally – in line with its key business focus of developing end-to-end diagnostic solutions which integrate its cell separation and enrichment technology with other analytical tests.

“By forging this strategic collaboration, Biolidics will be ideally positioned to increase the sales potential of our ClearCell FX1 System and CTChip FR1 biochip once these blood-based assays are approved clinically,” says Ivan Lew, executive director and CEO of Biolidics.

Shares in the group closed flat at 30 cents on Wednesday.

Counsel argue over how witnesses' conditioned statements were prepared and used

SINGAPORE (May 27): The prosecution and defence in the 2013 penny stock crash trial on May 23 crossed swords over how conditioned statements had been prepared and the relevance of questions raised in the cross-examination of these statements. Deputy public prosecutor Peter Koy said questions by the defence counsel for alleged co-conspirators John Soh Chee Wen and Quah Su-Ling were a “distraction from the facts”. “Questions as to what was shown to the witness, what trade and telephone data was shown to the witness and which data was filtered and shown to the witness are irrelevant t....
Read More >>

Briefs

SINGAPORE (May 27): “We believe that the president of the US is engaged in a cover-up.” — US House Speaker Nancy Pelosi, following a meeting with other Democratic Party leaders on whether or not to impeach US President Donald Trump. Singapore and Malaysia suspend intercity rail project The construction of a $1.4 billion rail project linking Singapore and Malaysia’s southern state of Johor has been suspended until Sept 30. The move, which was announced on May 21, was mutually agreed to by both of the countries’ transport ministers. “This does not mean we are terminating the....
Read More >>

Entropica Labs aims to provide insights for health sciences using quantum computing

SINGAPORE (May 27): Quantum computing used to be considered a technology bordering on science fiction. But thanks to recent developments in the field, this next generation of computing is now closer to reality than before. This is opening up possibilities for many practical applications that have attracted the attention of both large corporations and entrepreneurial start-ups. One of the start-ups is Entropica Labs, which aims to develop quantum computing software to solve complex problems in the field of molecular biology. This would provide doctors with a better understanding of human phy....
Read More >>